BioSight
Back
ALNYLAM PHARMACEUTICALS, INC. logo

ALNY

NASDAQCAMBRIDGE, MA
ALNYLAM PHARMACEUTICALS, INC.

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to treat genetic and acquired diseases. Alnylam has multiple approved products including AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO across various therapeutic areas, and maintains a pipeline of investigational RNAi candidates in clinical development. Alnylam is executing a long-term strategy called "Alnylam 2030" aimed at expanding its commercial presence and bringing additional RNAi therapeutics to market.

$309.49+17.57%1Y
ALNY · daily close · illustrative · 0 catalysts marked
1Y high$491.221Y low$251.15range$240.07(96%)past catalysts

Pipeline8

Nucresiran
Phase 3Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
Phase 3hATTR-PN
Phase 3Transthyretin Amyloidosis With Cardiomyopathy
small-molecule
Vutrisiran
Phase 3Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy
Phase 3hATTR-PN
Phase 3Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.

small-molecule
Zilebesiran
Phase 3High Risk Cardiovascular Disease
Phase 3Hypertension
Phase 3High Cardiovascular Risk
small-molecule
ALN-2232
Phase 2obesity
small-molecule
ALN-4324
Phase 2Obese or Overweight Healthy Volunteers
Phase 2Type 2 Diabetes Mellitus (T2DM)
small-molecule
ALN-6400
Phase 2Hereditary Hemorrhagic Telangiectasia
small-molecule
ALN-APP
Phase 2Cerebral Amyloid Angiopathy
small-molecule
Tirzepatide
Phase 2obesity

Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.

small-molecule

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.